14
Initially, Seattle-based Just – Evotec Biologics will receive US$28.6m from the Defense Health Agency (“DHA”) under a partnership announced earlier this summer. Under the terms of the agreement, production will take place on an as-needed basis over the next seven years at a flexible J.POD® manufacturing facility in Redmonton, USA, which currently is in the process of being completed. However, a highly efficient process for manufacturing has already been developed.
Just – Evotec Biologics has significant expertise in molecular optimisation, process and product development, which will become increasingly important following the emergence of…